Previous 10 | Next 10 |
Provides in-depth scientific and clinical data in R&D event today at 9:00 am ET Outlines data from two completed Phase 1 pharmacokinetic (PK) trials for AQST-108 (dipivefrin) sublingual film Articulates development strategy for second prodrug candidate, AQST-109 su...
Image source: The Motley Fool. Aquestive Therapeutics, Inc. (NASDAQ: AQST) Q4 2020 Earnings Call Mar 10, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Aquestive Therapeutics, Inc. (AQST) Q4 2020 Earnings Call Tran...
Aquestive Therapeutics, Inc. (AQST) Q4 2020 Earnings Conference Call March 10, 2021 08:00 ET Company Participants Stephanie Carrington - Investor Relations Keith Kendall - President and Chief Executive Officer Ernie Toth - Interim Chief Financial Officer Daniel Barber - Senior Vice President ...
Libervant™ (diazepam) Buccal Film New Drug Application (NDA) resubmission expected end of second quarter 2021 Epinephrine program and development strategy to be highlighted at a virtual investor event to be held at 9:00 a.m. ET on March 25, 2021 Entered U.S. licensing and...
WARREN, N.J., March 05, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that it will hos...
Aquestive Therapeutics (AQST) announced that it received written feedback from the FDA regarding its New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film for the management of seizure clusters.The guidance received from the regulator included the FDA’s expe...
Reaffirms plans to resubmit its New Drug Application (NDA) around the end of second quarter 2021 Received additional feedback from FDA after completion of Type A meeting and submission of revised weight based dosing regimen Anticipates an FDA action date in 2021 ...
WARREN, N.J., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that it will repo...
WARREN, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced the appointment o...
New hire helps lead Aquestive’s continued focus on its epinephrine program Provides update on Libervant™ (diazepam) Buccal Film WARREN, N.J., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused o...
News, Short Squeeze, Breakout and More Instantly...
Aquestive Therapeutics Inc. Company Name:
AQST Stock Symbol:
NASDAQ Market:
Aquestive Therapeutics Inc. Website:
Meets primary study endpoints with pharmacokinetics (PK) comparable whether Anaphylm is administered by subjects or by healthcare providers (HCPs) Final supportive study, the Oral Allergy Syndrome (OAS) challenge study, currently enrolling Continues to anticipate requesting a pr...
WARREN, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technolog...
WARREN, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technolog...